ANDA 211439, held by Hetero Labs Unit Iii. Dapagliflozin.
As of Nov 15, 2026, ANDA 211439 (Dapagliflozin), held by Hetero Labs Unit Iii, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 18, 2019 | Original application | Tentative approval |
| Dapagliflozin5MG · tablet;oral | Dapagliflozin | None (tentative approval) |
| Dapagliflozin10MG · tablet;oral | Dapagliflozin | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters